ANKRD52 is a regulatory subunit of protein phosphatase 6 (PP6) holoenzyme that functions in substrate recognition and phosphoprotein dephosphorylation 1. As a structural component of the PP6 complex alongside catalytic and scaffold subunits, ANKRD52 mediates dephosphorylation of signaling proteins including PAK1, thereby suppressing cell mobility and cancer metastasis 12. The ANKRD52 gene is subject to transcriptional regulation through multiple mechanisms: TAZ negatively inhibits ANKRD52 promoter activity in lung cancer 1, while circular intronic ANKRD52 RNA (ci-ankrd52) positively regulates its parent gene expression by enhancing Pol II transcriptional elongation 34. ANKRD52 functions as a tumor suppressor—reduced expression associates with late-stage lung cancer and poor prognosis across multiple cancer types, particularly kidney chr12 cancer 1. Conversely, ANKRD52 is targeted for downregulation by miR-423-5p and miR-17-92 cluster, with decreased expression correlating with advanced hepatocellular and other cancers 56. ANKRD52 expression correlates with immune cell infiltration and tumor microenvironment composition, suggesting potential utility as an immunotherapy biomarker 7. These findings position ANKRD52 as a PP6-dependent tumor suppressor with implications for cancer prognosis and therapeutic targeting.